(Nasdaq: PCVX), a clinical-stage vaccine innovation company, today announced that the first participants were dosed in the OPUS (OPA-based Pivotal U.S. Study) Phase 3 pivotal, noninferiority trial ...
Learn why child mortality is rising for the first time in our lives - and how smarter investments, innovation, and science ...
Merck , known as MSD outside the United States and Canada, announced today that the province of Saskatchewan has added CAPVAXIVE®, a 21-valent pneumococcal conjugate vaccine, to its publicly funded ...
Scientists engineered phages to act as scaffolds to carry silver nanoparticles. Together, the two bacteria-killing components ...
Pneumonia cases surge in winter as cold, pollution, and viruses weaken immunity. Dr. Agrawal urges early diagnosis, awareness ...
MedPage Today on MSN
How Has the Epidemiology of Meningitis Changed With Vaccine Advances?
Experts who spoke with MedPage Today also pointed to the impact of pneumococcal vaccines. Though a vaccine for adults was ...
Kite, a Gilead Company , presented a new analysis today demonstrating that second-line Yescarta® (axicabtagene ciloleucel) therapy offers consistent benefits in patients with relapsed/refractory large ...
WHO approves OS Therapies’ daznelimgene lisbac for non-proprietary name for product candidate OST-HER2: New York Thursday, November 27, 2025, 18:00 Hrs [IST] OS Therapies Inc, t ...
AMR MPTF saving lives and reducing economic loss in Zimbabwe ...
OS Therapies Inc. (NYSE American: OSTX) (“OS Therapies” or “the Company”), the world leader in listeria-based cancer ...
OS Therapies Inc. (NYSE American: OSTX) (“OS Therapies” or “the Company”), the world leader in listeria-based cancer ...
Detailed price information for Os Therapies Incorporated (OSTX-A) from The Globe and Mail including charting and trades.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback